Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Feb 20, 2024

Press releases

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 7, 2024

Press releases

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion announces that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Feb 1, 2024

Press releases

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Evaxion announces the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant.

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Jan 24, 2024

Press releases

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Evaxion announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).

Evaxion Announces Completion of ADS Ratio Change

Jan 22, 2024

Press releases

Evaxion Announces Completion of ADS Ratio Change

Evaxion today today announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.

BioStock Interview with CEO Christian Kanstrup

Jan 9, 2024

Presentations

BioStock Interview with CEO Christian Kanstrup

In this interview with BioStock, our CEO, Christian Kanstrup, discusses his vision for Evaxion, delving into AI, cancer, and partnerships.

Evaxion Announces Plan to Implement ADS Ratio Change

Jan 8, 2024

Press releases

Evaxion Announces Plan to Implement ADS Ratio Change

Evaxion today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). 

Evaxion Biotech Announces Closing of Private Placement

Dec 21, 2023

Press releases

Evaxion Biotech Announces Closing of Private Placement

Evaxion today announced the closing of its previously announced private placement (the “Private Placement”) with a gross proceed of $5.3 million.

Evaxion Biotech Announces Private Placement Financing

Dec 19, 2023

Press releases

Evaxion Biotech Announces Private Placement Financing

Evaxion is pleased to announce a private placement financing to raise gross proceeds of approximately $5.3 million.

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Dec 19, 2023

Press releases

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Evaxion today provided a business update and announced its third quarter 2023 financial results.

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Nov 28, 2023

Press releases

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Evaxion proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.

Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence

Nov 27, 2023

Publications

Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence

Publication: mBio
Authors: Sunita Gulati, Andreas Holm Mattsson, Sophie Schussek, Bo Zheng, Rosane B. DeOliveira, Jutamas Shaughnessy, Lisa A. Lewis, Peter A. Rice, Pär Comstedt, Sanjay Ram

Evaxion Media kit

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.